AU2007296899B2 - Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma - Google Patents

Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma Download PDF

Info

Publication number
AU2007296899B2
AU2007296899B2 AU2007296899A AU2007296899A AU2007296899B2 AU 2007296899 B2 AU2007296899 B2 AU 2007296899B2 AU 2007296899 A AU2007296899 A AU 2007296899A AU 2007296899 A AU2007296899 A AU 2007296899A AU 2007296899 B2 AU2007296899 B2 AU 2007296899B2
Authority
AU
Australia
Prior art keywords
antibody
fragment
afra
fab
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007296899A
Other languages
English (en)
Other versions
AU2007296899A1 (en
Inventor
Silvana Canevari
Margherita Cattozzo
Cioccio Vito Di
Mariangela Figini
Franck Martin
Giovanni Maurizi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Accelerator Applications SA
Istituto Nazionale per lo Studio e la Cura die Tumori
Original Assignee
Advanced Accelerator Applications SA
Istituto Nazionale per lo Studio e la Cura die Tumori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Accelerator Applications SA, Istituto Nazionale per lo Studio e la Cura die Tumori filed Critical Advanced Accelerator Applications SA
Publication of AU2007296899A1 publication Critical patent/AU2007296899A1/en
Assigned to ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI, DOMPE' S.P.A. reassignment ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI Request for Assignment Assignors: DOMPE PHA.R.MA S.P.A., ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI
Assigned to ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI, ADVANCED ACCELERATOR APPLICATIONS SA reassignment ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI Alteration of Name(s) of Applicant(s) under S113 Assignors: DOMPE' S.P.A., ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI
Application granted granted Critical
Publication of AU2007296899B2 publication Critical patent/AU2007296899B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2007296899A 2006-09-15 2007-09-12 Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma Active AU2007296899B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06019399A EP1900752A1 (en) 2006-09-15 2006-09-15 Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
EP06019399.2 2006-09-15
PCT/EP2007/007944 WO2008031577A1 (en) 2006-09-15 2007-09-12 Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma

Publications (2)

Publication Number Publication Date
AU2007296899A1 AU2007296899A1 (en) 2008-03-20
AU2007296899B2 true AU2007296899B2 (en) 2012-09-13

Family

ID=37737768

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007296899A Active AU2007296899B2 (en) 2006-09-15 2007-09-12 Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma

Country Status (14)

Country Link
US (1) US8388972B2 (https=)
EP (2) EP1900752A1 (https=)
JP (1) JP5513114B2 (https=)
KR (1) KR101497045B1 (https=)
AU (1) AU2007296899B2 (https=)
BR (1) BRPI0716811B8 (https=)
CA (1) CA2662005C (https=)
ES (1) ES2644423T3 (https=)
IL (1) IL197300A (https=)
MX (1) MX2009002711A (https=)
NZ (1) NZ575093A (https=)
RU (1) RU2464277C2 (https=)
WO (1) WO2008031577A1 (https=)
ZA (1) ZA200901328B (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3101034A1 (en) 2004-02-12 2016-12-07 Morphotek, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
CA2607444C (en) 2005-04-22 2015-03-10 Morphotek, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
TWI622402B (zh) * 2010-02-24 2018-05-01 免疫遺傳股份有限公司 葉酸受體１抗體類和免疫共軛物類及彼等之用途
WO2012033987A2 (en) * 2010-09-09 2012-03-15 Purdue Research Foundation Anti-human folate receptor beta antibodies and methods of use
MX343607B (es) * 2010-11-05 2016-11-11 Morphotek Inc Receptor alfa de folato como marcador de diagnóstico y pronóstico para cánceres que expresan receptor alfa de folato.
KR20140004174A (ko) 2011-01-18 2014-01-10 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암 치료를 위한 조성물 및 방법
CA2830628A1 (en) 2011-03-18 2012-09-27 Kagoshima University Composition for treatment and diagnosis of pancreatic cancer
BR112013025415B1 (pt) * 2011-04-01 2021-03-16 Immunogen, Inc uso de um imunoconjugado antirreceptor de folato 1 (folr1)
SI2731972T1 (en) * 2011-07-15 2018-04-30 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
WO2013026839A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
WO2013130776A1 (en) * 2012-02-29 2013-09-06 Purdue Research Foundation Folate receptor alpha binding ligands
US9200073B2 (en) * 2012-08-31 2015-12-01 Immunogen, Inc. Diagnostic assays and kits for detection of folate receptor 1
WO2014055771A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
EP4282419A1 (en) 2012-12-20 2023-11-29 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
CN113150145B (zh) 2013-08-30 2025-02-14 伊缪诺金公司 用于检测叶酸受体1的抗体和测定
PL3055332T3 (pl) * 2013-10-08 2020-02-28 Immunogen, Inc. Schematy dawkowania immunokoniugatu anty-FOLR1
KR101646577B1 (ko) * 2014-08-14 2016-08-09 원광대학교산학협력단 엽산수용체 표적용 화합물 또는 이의 약학적으로 허용가능한 염과, 이를 유효성분으로 포함하는 암 예방, 진단 또는 치료용 조성물
EP4141032B1 (en) 2014-11-20 2024-05-29 F. Hoffmann-La Roche AG Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
PT3221356T (pt) 2014-11-20 2020-10-29 Hoffmann La Roche Moléculas de ligação ao antigénio biespecíficas ativadoras das células t contra folr1 e cd3
DK3221357T3 (da) 2014-11-20 2020-08-10 Hoffmann La Roche Fælles letkæder og fremgangsmåder til anvendelse
CN116440279B (zh) 2015-09-17 2026-02-24 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
WO2018031980A1 (en) 2016-08-12 2018-02-15 L.E.A.F. Holdings Group Llc Polyglutamated antifolates and uses thereof
CN121177507A (zh) 2016-08-12 2025-12-23 L.E.A.F.控股集团公司 α和γ-D聚谷氨酸化抗叶酸剂及其用途
AU2018219887B2 (en) 2017-02-08 2024-08-15 Dragonfly Therapeutics, LLC Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CN110944661A (zh) 2017-02-20 2020-03-31 蜻蜓疗法股份有限公司 结合her2、nkg2d和cd16的蛋白质
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
ES3062820T3 (en) 2017-11-08 2026-04-14 L E A F Holdings Group Llc Platinum complexes and uses thereof
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
WO2019157129A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
EP3749318A4 (en) 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMATED RALTITREXED AND ITS USES
CA3090389A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated raltitrexed and uses thereof
US12310966B2 (en) 2018-02-07 2025-05-27 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
EP3749314A4 (en) 2018-02-07 2022-02-23 L.E.A.F Holdings Group LLC ALPHA-POLYGLUTAMATE METHOTREXATE AND ITS USES
CA3237846A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
BR112020015994A2 (pt) 2018-02-08 2020-12-15 Dragonfly Therapeutics, Inc. Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer
US12350271B2 (en) 2018-02-14 2025-07-08 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
JP7462950B2 (ja) 2018-02-14 2024-04-08 エル．イー．エー．エフ． ホールディングス グループ エルエルシー ガンマポリグルタミン酸化メトトレキセートおよびその使用
CA3090753A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated pralatrexate and uses thereof
WO2019160734A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
WO2019164930A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
AU2019225174B2 (en) 2018-02-23 2025-11-20 Endocyte, Inc. Sequencing method for CAR T cell therapy
AU2019236091B2 (en) 2018-03-13 2025-06-05 Phanes Therapeutics, Inc. Anti-folate receptor 1 antibodies and uses thereof
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
KR102835308B1 (ko) 2018-08-08 2025-07-21 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
MA55818A (fr) 2019-04-29 2022-03-16 Immunogen Inc Anticorps et immunoconjugués de fr-alpha biparatopique
US20230000997A1 (en) 2019-08-06 2023-01-05 L.E.A.F. Holdings Group Llc Processes of preparing polyglutamated antifolates and uses of their compositions
CN111393528B (zh) * 2020-01-19 2023-01-31 中国药科大学 一种靶向叶酸受体α的单链抗体及其应用
JP7512394B2 (ja) 2020-05-06 2024-07-08 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
CN117700557B (zh) * 2024-02-05 2024-04-30 卡秋(江苏)生物科技有限公司 一种特异性结合叶酸受体α的抗体或抗原结合片段
CN119757601A (zh) * 2025-01-06 2025-04-04 哈尔滨脉图精准技术有限公司 一种用于卵巢癌诊断的代谢标志物组合及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
AU2003244817B2 (en) * 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
EP3101034A1 (en) 2004-02-12 2016-12-07 Morphotek, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
CA2624923C (en) 2005-10-06 2016-06-07 Franck Martin Novel transformation selection system comprising pyrc gene complementation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FIGINI M. ET AL: "Panning Phage Antibody Libraries On Cells: Isolation Of Human Fab Fragments Against Ovarian Carcinoma Using Guided Selection" CANCER RESEARCH, vol. 58, no. 5, 1 March 1998, pages 991-996, *

Also Published As

Publication number Publication date
EP2061813A1 (en) 2009-05-27
US20100055034A1 (en) 2010-03-04
MX2009002711A (es) 2009-06-18
BRPI0716811B8 (pt) 2021-05-25
BRPI0716811B1 (pt) 2020-11-24
EP2061813B1 (en) 2017-07-19
WO2008031577A1 (en) 2008-03-20
JP5513114B2 (ja) 2014-06-04
IL197300A0 (en) 2011-08-01
KR101497045B1 (ko) 2015-02-27
ZA200901328B (en) 2010-05-26
BRPI0716811A2 (pt) 2013-11-05
JP2010503386A (ja) 2010-02-04
ES2644423T3 (es) 2017-11-28
KR20090059114A (ko) 2009-06-10
CA2662005A1 (en) 2008-03-20
CA2662005C (en) 2018-01-02
WO2008031577A8 (en) 2009-07-02
US8388972B2 (en) 2013-03-05
EP1900752A1 (en) 2008-03-19
NZ575093A (en) 2012-04-27
RU2009114161A (ru) 2010-10-20
AU2007296899A1 (en) 2008-03-20
IL197300A (en) 2016-02-29
RU2464277C2 (ru) 2012-10-20

Similar Documents

Publication Publication Date Title
AU2007296899B2 (en) Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
CN109963591B (zh) B7h3抗体-药物偶联物及其医药用途
JP6077745B2 (ja) 抗ポドプラニン抗体、及び抗ポドプラニン抗体を含む医薬組成物
US20170158755A1 (en) Anti-laminin4 antibodies specific for lg1-3
US20250011427A1 (en) Anti-cd3 antibodies with cross-reactivity to human and cynomolgus proteins
CA3203257A1 (en) Anti-b7-h3 antibody and uses thereof
TW202442681A (zh) 抗ror1抗體及其藥物偶聯物
US20240417469A1 (en) Cd3-targeting t-cell engagers with improved therapeutic index
KR20250042144A (ko) Itga2를 표적으로 하는 항체 및 이를 포함하는 항체-약물 접합체(antibody targeting itga2 and antibody-drug conjugate comprising the same)
JP2025520692A (ja) 抗ｓｌｃ３４ａ２モノクローナル抗体およびその使用
US20240026004A1 (en) ANTI-PD-L1/TGF-ß BIFUNCTIONAL ANTIBODY AND USE THEREOF
WO2025131054A1 (en) Antibody drug conjugates targeting to b7-h3 and egfr and the use thereof
WO2025195495A1 (zh) 一种放射性核素偶联物及其制备方法和用途
HK40110049A (zh) 对人和食蟹猴蛋白具有交叉反应性的抗cd3抗体
CN120025446A (zh) 结合分子及抗体药物偶联物和用途
KR20250174736A (ko) L1cam을 표적화하는 항체 및 이의 용도
TW202539735A (zh) 一種包含特異性結合ｄｌｌ３和ｃｄ３的雙特異性抗體的醫藥組成物
CN117402255A (zh) 抗人pd-l1和人ox40的双特异抗体及其应用
HK40108102A (zh) 具有改善的治疗指数的靶向cd3的t细胞衔接器
HK40120912A (zh) 结合分子及抗体药物偶联物和用途
CN121335923A (zh) Ceacam1靶向抗体及其用途
BR112018005837B1 (pt) Anticorpo anti-mesotelina, ácido nucleico, vetor, célula hospedeira, método de preparação do anticorpo e composição farmacêutica

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUM

Free format text: FORMER APPLICANT(S): DOMPE PHA.R.MA S.P.A.; ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI

FGA Letters patent sealed or granted (standard patent)